Overview
Immunotherapy now has become an integral part of the management of advanced NSCLC. There is now an interest in evaluating these agents in the earlier stages of NSCLC. In this webinar we will:
- Discuss the current clinical data addressing the use of immunotherapy in patients with early-stage or locally advanced NSCLC.
- Identify ongoing clinical trials assessing the utility of these agents in early and locally advanced NSCLC patients.
- Demonstrate an update as to the status of next generation immunotherapeutic agents under clinical development.
Shirish M. Gadgeel, MD
Mary Lou Kennedy Research Professor in Thoracic Oncology, Co-Leader of Thoracic Oncology Research Program, Associate Director for Cancer Care at Networking and Affiliated Centers, Professor, Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, Michigan.
Ramaswamy Govindan, MD - Program Chair
Director, Section of Medical Oncology, Professor of Medicine, Anheuser-Busch Endowed Chair in Medical Oncology, Director, Section of Oncology, Washington University School of Medicine.
For any inquiries, please contact meetings@iaslc.org.
Shirish M. Gadgeel, MD
Mary Lou Kennedy Research Professor in Thoracic Oncology, Co-Leader of Thoracic Oncology Research Program, Associate Director for Cancer Care at Networking and Affiliated Centers, Professor, Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor, Michigan.
Ramaswamy Govindan, MD - Program Chair
Director, Section of Medical Oncology, Professor of Medicine, Anheuser-Busch Endowed Chair in Medical Oncology, Director, Section of Oncology, Washington University School of Medicine.
For any inquiries, please contact meetings@iaslc.org.